Review



fda approved antivirals remdesivir  (Gilead Sciences)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 99
      Buy from Supplier

    Structured Review

    Gilead Sciences fda approved antivirals remdesivir
    Fig. 3. Drug-protein docking poses of wild-type CYP3A4/5 and their mutants showing the lowest docking scores. (a) <t>remdesivir</t> docking pose with CYP3A4-Wild-type (b) nirmatrelvir docking pose with CYP3A4-Wild-type (c) ritonavir docking pose with CYP3A4-Wild-type, (d) remdesivir docking pose with CYP3A4- R130P (e) nirmatrelvir docking pose with CYP3A4- I335T[*32] (f) ritonavir docking pose with CYP3A4- R418T, (g) remdesivir docking pose with CYP3A5-Wild-type (h) nirmatrelvir docking pose with CYP3A5-Wild-type (i) ritonavir docking pose with CYP3A5-Wild-type, (j) remdesivir docking pose with CYP3A5-L133P (k) nirmatrelvir docking pose with CYP3A5-I335T (l) ritonavir docking pose with CYP3A5- R130Q.
    Fda Approved Antivirals Remdesivir, supplied by Gilead Sciences, used in various techniques. Bioz Stars score: 99/100, based on 15423 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fda+antivirals/VEKLURY/pm39819897-55-26-28
    Average 99 stars, based on 15423 article reviews
    fda approved antivirals remdesivir - by Bioz Stars, 2026-09
    99/100 stars

    Images

    1) Product Images from "In-silico screening and analysis of missense SNPs in human CYP3A4/5 affecting drug-enzyme interactions of FDA-approved COVID-19 antiviral drugs."

    Article Title: In-silico screening and analysis of missense SNPs in human CYP3A4/5 affecting drug-enzyme interactions of FDA-approved COVID-19 antiviral drugs.

    Journal: Scientific reports

    doi: 10.1038/s41598-025-85595-x

    Fig. 3. Drug-protein docking poses of wild-type CYP3A4/5 and their mutants showing the lowest docking scores. (a) remdesivir docking pose with CYP3A4-Wild-type (b) nirmatrelvir docking pose with CYP3A4-Wild-type (c) ritonavir docking pose with CYP3A4-Wild-type, (d) remdesivir docking pose with CYP3A4- R130P (e) nirmatrelvir docking pose with CYP3A4- I335T[*32] (f) ritonavir docking pose with CYP3A4- R418T, (g) remdesivir docking pose with CYP3A5-Wild-type (h) nirmatrelvir docking pose with CYP3A5-Wild-type (i) ritonavir docking pose with CYP3A5-Wild-type, (j) remdesivir docking pose with CYP3A5-L133P (k) nirmatrelvir docking pose with CYP3A5-I335T (l) ritonavir docking pose with CYP3A5- R130Q.
    Figure Legend Snippet: Fig. 3. Drug-protein docking poses of wild-type CYP3A4/5 and their mutants showing the lowest docking scores. (a) remdesivir docking pose with CYP3A4-Wild-type (b) nirmatrelvir docking pose with CYP3A4-Wild-type (c) ritonavir docking pose with CYP3A4-Wild-type, (d) remdesivir docking pose with CYP3A4- R130P (e) nirmatrelvir docking pose with CYP3A4- I335T[*32] (f) ritonavir docking pose with CYP3A4- R418T, (g) remdesivir docking pose with CYP3A5-Wild-type (h) nirmatrelvir docking pose with CYP3A5-Wild-type (i) ritonavir docking pose with CYP3A5-Wild-type, (j) remdesivir docking pose with CYP3A5-L133P (k) nirmatrelvir docking pose with CYP3A5-I335T (l) ritonavir docking pose with CYP3A5- R130Q.

    Techniques Used:

    Related Articles

    Binding Assay:

    Article Title: <em></em><strong><em>In silico</em> Repositioning for Dual Inhibitor Discovery of SARS-CoV-2 (COVID-19) 3C-like Protease and Papain-like Peptidase</strong>
    Article Snippet: 3.4.3. in silico study of proposed dual inhibitor over SARS-CoV-2 3CLpro and PLpro active site The identical structures over the two active sites including; Nelfinavir, Valaganciclovir, Merimepodib, Inarigivir, Remdesivir, Taribavirine and TAS106 exist in both screening results based on considerable binding affinities for both target protease enzymes (Tables 1, 2 and 3 compounds highlighted in yellow color). .. Figures 7 represent chemical structures of the proposed dual inhibitors in which Valganciclovir and Nelfinavir are known FDA antivirals and the rest are under investigation agent (Inarigivir, Remdesivir, Merimepodib, Taribavirin, TAS-106) (Table 2) Figure 9 depicts the binding interaction of these compounds over 3CLpro. ..



    Similar Products

    fda approved antivirals remdesivir  (Gilead Sciences)
    99
    Gilead Sciences fda approved antivirals remdesivir
    Fig. 3. Drug-protein docking poses of wild-type CYP3A4/5 and their mutants showing the lowest docking scores. (a) <t>remdesivir</t> docking pose with CYP3A4-Wild-type (b) nirmatrelvir docking pose with CYP3A4-Wild-type (c) ritonavir docking pose with CYP3A4-Wild-type, (d) remdesivir docking pose with CYP3A4- R130P (e) nirmatrelvir docking pose with CYP3A4- I335T[*32] (f) ritonavir docking pose with CYP3A4- R418T, (g) remdesivir docking pose with CYP3A5-Wild-type (h) nirmatrelvir docking pose with CYP3A5-Wild-type (i) ritonavir docking pose with CYP3A5-Wild-type, (j) remdesivir docking pose with CYP3A5-L133P (k) nirmatrelvir docking pose with CYP3A5-I335T (l) ritonavir docking pose with CYP3A5- R130Q.
    Fda Approved Antivirals Remdesivir, supplied by Gilead Sciences, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fda+antivirals/VEKLURY/pm39819897-55-26-28
    Average 99 stars, based on 1 article reviews
    fda approved antivirals remdesivir - by Bioz Stars, 2026-09
    99/100 stars
    		  Buy from Supplier
    fda approved antiviral drugs  (Gilead Sciences)
    99
    Gilead Sciences fda approved antiviral drugs
    Fig. 3. Drug-protein docking poses of wild-type CYP3A4/5 and their mutants showing the lowest docking scores. (a) <t>remdesivir</t> docking pose with CYP3A4-Wild-type (b) nirmatrelvir docking pose with CYP3A4-Wild-type (c) ritonavir docking pose with CYP3A4-Wild-type, (d) remdesivir docking pose with CYP3A4- R130P (e) nirmatrelvir docking pose with CYP3A4- I335T[*32] (f) ritonavir docking pose with CYP3A4- R418T, (g) remdesivir docking pose with CYP3A5-Wild-type (h) nirmatrelvir docking pose with CYP3A5-Wild-type (i) ritonavir docking pose with CYP3A5-Wild-type, (j) remdesivir docking pose with CYP3A5-L133P (k) nirmatrelvir docking pose with CYP3A5-I335T (l) ritonavir docking pose with CYP3A5- R130Q.
    Fda Approved Antiviral Drugs, supplied by Gilead Sciences, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fda+antivirals/VEKLURY/pm37995824-46-1-6
    Average 99 stars, based on 1 article reviews
    fda approved antiviral drugs - by Bioz Stars, 2026-09
    99/100 stars
    		  Buy from Supplier
    multitarget sars cov 2 antivirals  (Selleck Chemicals)
    96
    Selleck Chemicals multitarget sars cov 2 antivirals
    Fig. 3. Drug-protein docking poses of wild-type CYP3A4/5 and their mutants showing the lowest docking scores. (a) <t>remdesivir</t> docking pose with CYP3A4-Wild-type (b) nirmatrelvir docking pose with CYP3A4-Wild-type (c) ritonavir docking pose with CYP3A4-Wild-type, (d) remdesivir docking pose with CYP3A4- R130P (e) nirmatrelvir docking pose with CYP3A4- I335T[*32] (f) ritonavir docking pose with CYP3A4- R418T, (g) remdesivir docking pose with CYP3A5-Wild-type (h) nirmatrelvir docking pose with CYP3A5-Wild-type (i) ritonavir docking pose with CYP3A5-Wild-type, (j) remdesivir docking pose with CYP3A5-L133P (k) nirmatrelvir docking pose with CYP3A5-I335T (l) ritonavir docking pose with CYP3A5- R130Q.
    Multitarget Sars Cov 2 Antivirals, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fda+antivirals/FDA-approved+Drug+Library/pm36244310-97-4-21
    Average 96 stars, based on 1 article reviews
    multitarget sars cov 2 antivirals - by Bioz Stars, 2026-09
    96/100 stars
    		  Buy from Supplier
    fda approved antiviral drug against sars cov  (Gilead Sciences)
    99
    Gilead Sciences fda approved antiviral drug against sars cov
    Primary Outcome. (A) Mean log <t>SARS-CoV-2</t> viral RNA in placebo compared to atovaquone over the 10-days trial period. (B) Viral load decline in placebo and atovaquone groups. No statistically significant difference was detected between the two groups.
    Fda Approved Antiviral Drug Against Sars Cov, supplied by Gilead Sciences, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fda+antivirals/VEKLURY/pmc09561237-38-4-11
    Average 99 stars, based on 1 article reviews
    fda approved antiviral drug against sars cov - by Bioz Stars, 2026-09
    99/100 stars
    		  Buy from Supplier
    us fda approved drugs  (Selleck Chemicals)
    93
    Selleck Chemicals us fda approved drugs
    The output compounds from fitting of the <t> US-FDA approved </t> database in the generated structure-based pharmacophore
    Us Fda Approved Drugs, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fda+antivirals/Antiviral+Compound+Library/pmc09366421-93-16-22
    Average 93 stars, based on 1 article reviews
    us fda approved drugs - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    fda us approved database  (Selleck Chemicals)
    93
    Selleck Chemicals fda us approved database
    The output compounds from fitting of the <t> US-FDA approved </t> database in the generated structure-based pharmacophore
    Fda Us Approved Database, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fda+antivirals/Antiviral+Compound+Library/pmc09366421-56-10-16
    Average 93 stars, based on 1 article reviews
    fda us approved database - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    fda approved antiviral drugs monensin  (Gilead Sciences)
    99
    Gilead Sciences fda approved antiviral drugs monensin
    The output compounds from fitting of the <t> US-FDA approved </t> database in the generated structure-based pharmacophore
    Fda Approved Antiviral Drugs Monensin, supplied by Gilead Sciences, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fda+antivirals/VEKLURY/pm33459176-90-1-6
    Average 99 stars, based on 1 article reviews
    fda approved antiviral drugs monensin - by Bioz Stars, 2026-09
    99/100 stars
    		  Buy from Supplier
    fda approved antiviral treatment  (Gilead Sciences)
    99
    Gilead Sciences fda approved antiviral treatment
    The output compounds from fitting of the <t> US-FDA approved </t> database in the generated structure-based pharmacophore
    Fda Approved Antiviral Treatment, supplied by Gilead Sciences, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fda+antivirals/VEKLURY/pm35255177-13-32-38
    Average 99 stars, based on 1 article reviews
    fda approved antiviral treatment - by Bioz Stars, 2026-09
    99/100 stars
    		  Buy from Supplier

    Image Search Results


    Fig. 3. Drug-protein docking poses of wild-type CYP3A4/5 and their mutants showing the lowest docking scores. (a) remdesivir docking pose with CYP3A4-Wild-type (b) nirmatrelvir docking pose with CYP3A4-Wild-type (c) ritonavir docking pose with CYP3A4-Wild-type, (d) remdesivir docking pose with CYP3A4- R130P (e) nirmatrelvir docking pose with CYP3A4- I335T[*32] (f) ritonavir docking pose with CYP3A4- R418T, (g) remdesivir docking pose with CYP3A5-Wild-type (h) nirmatrelvir docking pose with CYP3A5-Wild-type (i) ritonavir docking pose with CYP3A5-Wild-type, (j) remdesivir docking pose with CYP3A5-L133P (k) nirmatrelvir docking pose with CYP3A5-I335T (l) ritonavir docking pose with CYP3A5- R130Q.

    Journal: Scientific reports

    Article Title: In-silico screening and analysis of missense SNPs in human CYP3A4/5 affecting drug-enzyme interactions of FDA-approved COVID-19 antiviral drugs.

    doi: 10.1038/s41598-025-85595-x

    Figure Lengend Snippet: Fig. 3. Drug-protein docking poses of wild-type CYP3A4/5 and their mutants showing the lowest docking scores. (a) remdesivir docking pose with CYP3A4-Wild-type (b) nirmatrelvir docking pose with CYP3A4-Wild-type (c) ritonavir docking pose with CYP3A4-Wild-type, (d) remdesivir docking pose with CYP3A4- R130P (e) nirmatrelvir docking pose with CYP3A4- I335T[*32] (f) ritonavir docking pose with CYP3A4- R418T, (g) remdesivir docking pose with CYP3A5-Wild-type (h) nirmatrelvir docking pose with CYP3A5-Wild-type (i) ritonavir docking pose with CYP3A5-Wild-type, (j) remdesivir docking pose with CYP3A5-L133P (k) nirmatrelvir docking pose with CYP3A5-I335T (l) ritonavir docking pose with CYP3A5- R130Q.

    Article Snippet: Moreover, we aimed to distinguish deleterious from benign SNPs, and then perform SNP modelling and molecular docking simulations to predict enzyme-drug interactions using the EMA and FDA-approved antivirals remdesivir and nirmatrelvir/ritonavir 20,21.

    Techniques:

    Primary Outcome. (A) Mean log SARS-CoV-2 viral RNA in placebo compared to atovaquone over the 10-days trial period. (B) Viral load decline in placebo and atovaquone groups. No statistically significant difference was detected between the two groups.

    Journal: Frontiers in Pharmacology

    Article Title: Atovaquone for treatment of COVID-19: A prospective randomized, double-blind, placebo-controlled clinical trial

    doi: 10.3389/fphar.2022.1020123

    Figure Lengend Snippet: Primary Outcome. (A) Mean log SARS-CoV-2 viral RNA in placebo compared to atovaquone over the 10-days trial period. (B) Viral load decline in placebo and atovaquone groups. No statistically significant difference was detected between the two groups.

    Article Snippet: For example, the first FDA approved antiviral drug against SARS-CoV-2 was remdesivir, which was originally developed for the Ebola virus, and has been successfully repurposed as a SARS-CoV-2 RNA polymerase inhibitor.

    Techniques:

    Correlation Between Atovaquone Plasma Concentration and Viral Load. Mean log SARS-CoV-2 viral RNA showed an inverse correlation with atovaquone plasma concentration (rho −0.54, p-0.005).

    Journal: Frontiers in Pharmacology

    Article Title: Atovaquone for treatment of COVID-19: A prospective randomized, double-blind, placebo-controlled clinical trial

    doi: 10.3389/fphar.2022.1020123

    Figure Lengend Snippet: Correlation Between Atovaquone Plasma Concentration and Viral Load. Mean log SARS-CoV-2 viral RNA showed an inverse correlation with atovaquone plasma concentration (rho −0.54, p-0.005).

    Article Snippet: For example, the first FDA approved antiviral drug against SARS-CoV-2 was remdesivir, which was originally developed for the Ebola virus, and has been successfully repurposed as a SARS-CoV-2 RNA polymerase inhibitor.

    Techniques: Concentration Assay

    The output compounds from fitting of the US-FDA approved database in the generated structure-based pharmacophore

    Journal: RSC Advances

    Article Title: Remdesivir analog as SARS-CoV-2 polymerase inhibitor: virtual screening of a database generated by scaffold replacement

    doi: 10.1039/d2ra00486k

    Figure Lengend Snippet: The output compounds from fitting of the US-FDA approved database in the generated structure-based pharmacophore

    Article Snippet: The generated pharmacophore was validated by pharmacophore search for a decoy test set consists of 302 US-FDA approved drugs (Antiviral Library from Selleck, Catalog No. L7000) for the treatment of SARS-CoV2.

    Techniques: Generated